Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...

The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.

Accessed March 2025. 4 Johnson & Johnson Innovative Medicine. TREMFYA ® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative ...

3 "The results from the Phase 3 studies demonstrate guselkumab has the potential to become the only ... European Medicines Agency. Updated TREMFYA Summary of Product Characteristics. Accessed March ...

Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...

Tremfya (guselkumab) – J&J’s follow-up to blockbuster IL-12 and IL-23 inhibitor Stelara (ustekinumab) – has been approved in the US for moderate-to-severe plaque psoriasis since 2017.

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

Tremfya (guselkumab) is also the only drug in the class to achieve clinical remission and endoscopic response at one year with a fully subcutaneous treatment regimen, according to the drugmaker.